Targeson Inc. Presents at 14th International Symposium on Anti-Angiogenic Therapy

San Diego, CA. – January 26, 2012 - Targeson Vice President of Research and Development, Joshua Rychak, PhD will be presenting “Ultrasound Molecular Imaging of Tumor Angiogenesis” at the 14th International Symposium on Anti-Angiogenic Therapy, February 2 - 4, 2012.  The Symposium is conducted by The University of Texas MD Anderson Cancer Center and will be held at the Hyatt Regency La Jolla in San Diego.

Contrast ultrasound is an emerging imaging technique for imaging tumor progression, both in a clinical and research setting. The advent of microsphere ultrasound contrast agents has expanded the use of ultrasound into molecular and functional imaging. In particular, the targeted microsphere agents developed and manufactured by Targeson are now being utilized as contrast agents for molecular imaging of angiogenesis in basic science and the drug development process. 

Dr. Rychak will present the Company’s work on the development of several angiogenesis-targeted microsphere contrast agents for ultrasound imaging of tumor vasculature. Distinct formulation strategies for targeting alpha-v beta-3 integrin and VEGFR2 were developed by Targeson, and imaging efficacy was examined in mouse and canine models of disease. Targeson’s angiogenesis-targeted agent portfolio provides a unique set of imaging tools for researchers engaged in cancer research, both in academia and the biopharmaceutical research industry.

About Targeson, Inc.

Targeson develops, manufactures and markets ultrasound imaging agents for functional and molecular imaging applications in the research market. Targeson’s commercial products include: Targestar® P, a non-targeted ultrasound contrast agent designed to enhance and quantify blood flow and vascular function; Targestar P-HF, a perfusion contrast agent specifically designed to be used with high frequency ultrasound scanners; Targestar SA, a targetable ultrasound contrast agent enabling any biotinylated antibody or biomolecule to be coupled to a microsphere, making it suitable for a wide variety of molecular imaging applications including tumor angiogenesis, myocardial infarction, atherosclerotic plaque, thrombosis, organ transplant rejection and inflammatory diseases; Visistar® Integrin, a targeted ultrasound contrast agent coated with a peptide that binds integrin αvβ3; Visistar VEGFR2, a targeted ultrasound contrast agent coated with a VEGFR2 binding ligand, both indicated for molecular imaging of angiogenesis and tumor growth; Visistar VCAM-1, a targeted ultrasound contrast agent indicated for molecular imaging of inflammation; and Targesphere™, a delivery agent for transfection.

For further information please contact 877-290-4043/858-427-3675 or info@targeson.com

Targestar and Visistar are registered trademarks and Targesphere™, is a pending trademark of Targeson, Inc.